Protalix BioTherapeutics (PLX) Leases (2019 - 2025)
Protalix BioTherapeutics (PLX) has 7 years of Leases data on record, last reported at $7.8 million in Q3 2025.
- For Q3 2025, Leases rose 38.35% year-over-year to $7.8 million; the TTM value through Sep 2025 reached $7.8 million, up 38.35%, while the annual FY2024 figure was $5.4 million, 8.11% down from the prior year.
- Leases reached $7.8 million in Q3 2025 per PLX's latest filing, up from $5.0 million in the prior quarter.
- Across five years, Leases topped out at $7.8 million in Q3 2025 and bottomed at $4.8 million in Q2 2022.
- Average Leases over 5 years is $5.5 million, with a median of $5.4 million recorded in 2021.
- The widest YoY moves for Leases: up 38.35% in 2025, down 12.79% in 2025.
- A 5-year view of Leases shows it stood at $5.0 million in 2021, then grew by 2.56% to $5.1 million in 2022, then grew by 16.16% to $5.9 million in 2023, then fell by 8.11% to $5.4 million in 2024, then skyrocketed by 43.83% to $7.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $7.8 million in Q3 2025, $5.0 million in Q2 2025, and $5.2 million in Q1 2025.